The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of ...

BioNTech (BNTX) ADRs lost ~5% in the premarket on Thursday after Bloomberg News reported that Pfizer (PFE) is planning to sell its remaining stake in its partner, which helped the U.S. pharma giant to ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has actually seen in full. What happens when Madrid finally puts the complete data ...

Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination. For pharmacists counseling patients this ...

The deal comes as BioNTech works to complete the $1.25 billion acquisition of CureVac that it announced in June. (Avosb/iStock/Getty Images Plus) The chapter on Pfizer and BioNTech’s mRNA patent feud ...

Add Yahoo as a preferred source to see more of our stories on Google. Pfizer Inc. signage is seen on July 22, 2020 in New York City. Pfizer and partner BioNTech said they will halt a ...

A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an ...

London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to reverse a prior High Court ruling that granted a patent win to their rival ...

Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.